Literature DB >> 22385925

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Hee Kyung Ahn1, Boram Han, Su Jin Lee, Taekyu Lim, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park.   

Abstract

Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22385925     DOI： 10.1016/j.lungcan.2012.02.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  11 in total

Review 1.  Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

Authors:  Panagiota Economopoulou; Giannis Mountzios
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors:  Sai-Hong Ignatius Ou; Karen R Sommers; Michele C Azada; Edward B Garon
Journal:  Oncologist       Date:  2015-01-07

3.  Sustained release of methotrexate through liquid-crystalline folate nanoparticles.

Authors:  Rahul Misra; Sanat Mohanty
Journal:  J Mater Sci Mater Med       Date:  2014-06-22       Impact factor: 3.896

Review 4.  Leptomeningeal Metastases.

Authors:  Jerome J Graber; Santosh Kesari
Journal:  Curr Treat Options Oncol       Date:  2018-01-23

5.  Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Authors:  Justin F Gainor; Carol A Sherman; Kathryn Willoughby; Jennifer Logan; Elizabeth Kennedy; Priscilla K Brastianos; Andrew S Chi; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

6.  Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.

Authors:  Puyuan Xing; Shouzheng Wang; Xuezhi Hao; Tongtong Zhang; Junling Li
Journal:  Oncotarget       Date:  2016-12-20

Review 7.  Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.

Authors:  Maria Krchniakova; Jan Skoda; Jakub Neradil; Petr Chlapek; Renata Veselska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 8.  [Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer].

Authors:  Yan Xu; Longyun Li; Mengzhao Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-10-20

Review 9.  Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.

Authors:  Ana Turkaj; Anna M Morelli; Tiziana Vavalà; Silvia Novello
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

10.  [Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].

Authors:  Zhiqin Lu; Jing Cai; Zhimin Zeng; Anwen Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.